Because certain amino acid transporters are significantly overexpressed on the surface of breast cancer cells, they can be selected as efficient targets for active targeting of tumor-specific nanocarriers, enabling the delivery of modified chemotherapy drugs. This evidence concerns the gene SLC38A7 and breast carcinoma.